
INVITATION



Heart Failure Quality Improvement Webinar

Wednesday 30th June 2021 7:00pm – 8:30pm

A quality improvement toolkit for heart failure management in primary care, utilising the PDSA cycle framework

HeartPlan in a box quality improvement (QI)

toolkit is intended to support general practitioners and primary care teams in undertaking QI activities to improve the quality of care for their patients with heart failure. It is developed by Novartis Australia with the guidance of a multidisciplinary steering committee of heart failure experts.

AGENDA

7:00pm Welcome and Introduction

7:05pm Unmet Need of Heart Failure: The View from Primary Care

A/Professor Ralph Audehm

7:50pm Q&A

8:00pm HeartPlan in a Box. A Quality Improvement Toolkit for general

practice Suzanne Blackeby

8:25pm Q&A

8:30pm Meeting close

To register your interest in attending the Heart Failure Quality Improvement Webinar, please click on the following link: Click here with your name, position, practice name, email, telephone and clinic software.

General Practitioners, Nurses and Practice Managers are encouraged to attend.





SPEAKERS





Associate Professor Ralph Audehm

General Practitioner, Melbourne Vic

A/Professor Ralph Audehm is a general practitioner with over 30 years of experience. He has a long- standing interest in the management of heart failure in general practice and has initiated and supported many initiatives to systematically improve health outcomes for people with heart disease.

A/Professor Audehm has been a member of numerous boards, expert panels and working parties and is a co-author of the *National Heart Foundation of Australia and Cardiac Society of*

Australia and New Zealand Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. In 2004 he was made an Honorary Research Fellow and, in 2015, a Clinical Associate Professor of the University of Melbourne.



Ms Suzanne Blackeby

Nurse Educator, Australian Primary
Health Care Nurses Association (APNA), Sydney NSW
Ms Suzanne Blackeby is a registered nurse working hands-on in
primary-care leadership as the nurse educator for the Australian
Primary Care Nurses Association (APNA). APNA's goals of promoting
nurses in the primary-care space to be 'Valued, Visible and

Respected' are those that she is keen to promote across general practice, aged care, justice health, community health and educational settings, as nurses continue to be the largest workforce in the health sector. Ms Blackeby is a consultant for primary care, disability policy and nursing education. She has a special interest and drive to see change in the way people from marginalised groups are treated when they need to access health care.

Privacy Information

Your personal information will be processed in accordance with the Novartis Privacy Policy at https://www.novartis.com.au/privacy-policy. Your information, including any information forwarded to the Novartis Patient Safety department, may be processed and stored on servers located in jurisdictions outside of the country in which it was collected.

You consent to Novartis using your personal information to communicate with you about Novartis products and services, and to invite you to, or arrange your participation in, activities managed by Novartis. You are not obliged to provide personal information, however if you do not, you may not be able to participate fully in activities managed by Novartis. You have the right to access, update or correct your personal information or decline to receive marketing communications from Novartis. To find out how, please refer to the Novartis Privacy Policy. Novartis is committed to Patient Safety. In accordance with regulatory obligations for reporting safety information Novartis processes reports of adverse events experienced by patients on Novartis products when identified by a Novartis representative (or by a third party acting on behalf of Novartis.) Novartis Patient Safety may contact you or your healthcare professional in order to collect further information on the adverse event. This information may be shared with health authorities or other pharmaceutical companies with whom Novartis has a license agreement, and third parties we work with for the purpose of safety reporting.

In accordance with the Code of Conduct for the prescription medicine industry in Australia, any costs (for example travel or meals) incurred by a partner/spouse, guest or family member travelling with a healthcare professional must not be paid for or subsidised by the company. Novartis Pharmaceuticals Australia Pty Limited. ABN 18 004 244 160. 54 Waterloo Road, Macquarie Park NSW 2113. Ph (02) 9805 3555. May 2021. AU-16680

References: 1. Chen L et al. Snapshot of heart failure in Australia. Mary MacKillop Institute for Health Research. 2017. 2. Atherton J et al. Heart Lung Circ 2018; 27: 1123–1208.



